In 2018, BIO-Europe will be hosted for the first time in Copenhagen, close to our Danish R&D facilities. The event will take place at Bella Center on 5–7 November. Novo Nordisk’s participation will focus on our research in diabetes, atherosclerosis and NASH (non-alcoholic steatohepatitis) as well as our work with stem cell-based therapy.
As a global healthcare provider, Novo Nordisk's key contribution is to discover and develop innovative medicines. Chief Science Officer Mads Krogsgaard Thomsen explains how we "innovate to improve the lives of people living with diabetes and other serious chronic diseases worldwide".
We are looking to work with external partners that have complementary expertise to our own, both across our therapy areas and within each step of the pharmaceutical value chain.
Novo Nordisk's research and development facilities in Denmark, USA, UK, India and China form a global network that covers the entire pharmaceutical value chain across our therapy areas.